分析重组组织型纤溶酶原激活剂早期静脉溶栓对急性脑梗死的临床效果

Analysis of Clinical Effects of Early Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator on Acute Cerebral Infarction

目的:研究分析重组组织型纤溶酶激活剂早期静脉溶栓在急性脑梗死治疗的临床效果。方法:选取2018年5月-2019年5月于本院就诊的急性脑梗死(发病≤6 h)患者78例,应用随机数字表法分组为观察组和对照组,各39例。观察组应用重组组织型纤溶酶原激活剂(rt-PA)进行早期静脉溶栓治疗,对照组应用尿激酶(UK)进行溶栓治疗,比较两组凝血指标、神经功能缺损评分(NIHSS)、临床疗效以及不良事件发生率。结果:两组患者治疗后血小板均有降低,差异均无统计学意义(P>0.05);在治疗后2 h,观察组的D-二聚体、纤维蛋白降解产物水平高于对照组,差异均有统计学意义(P<0.05);治疗后观察组NIHSS评分均低于对照组,差异均有统计学意义(P<0.05);观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05);观察组不良事件发生率与对照组相比,差异无统计学意义(P>0.05)。结论:重组组织型纤溶酶激活剂早期静脉溶栓治疗急性脑梗死有较好疗效,且存在一定安全性。

Objective:To study and analyze the clinical effects of early intravenous thrombolysis with Recombinant Tissue Plasmin Activator in the treatment of acute cerebral infarction.Method:A total of 78 patients with acute cerebral infarction(onset≤6 h)in our hospital from May 2018 to May 2019 were selected.According to the random number table method,they divided into observation group and control group,39 cases in each group.The observation group was treated with Recombinant Tissue Plasminogen Activator(rt-PA)for early intravenous thrombolysis,and the control group was treated with Urokinase(UK)for thrombolytic therapy.The coagulation index,NIHSS,clinical effect and incidence of adverse events were compared between the two groups.Result:Platelets were decreased after treatment in both groups,and the differences were not statistically significant(P>0.05).At 2 hour after treatment,the levels of D-dimer and fibrin degradation products in the observation group were higher than those in the control group.The differences were statistically significant(P<0.05);the NIHSS score of the observation group were lower than that of the control group after treatment,the differences were statistically significant(P<0.05);the total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse events between the observation group and the control group(P>0.05).Conclusion:The early intravenous thrombolytic therapy with Recombinant Tissue Plasmin Activator has a good curative effect on acute cerebral infarction,and it has certain safety.